Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.

[1]  C. Gridelli,et al.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. , 2015, The Lancet. Oncology.

[2]  C. Gridelli,et al.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[3]  D. Vordermark,et al.  Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. , 2015, International journal of radiation oncology, biology, physics.

[4]  R. Navari,et al.  Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. , 2015 .

[5]  A. Feizi,et al.  The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting , 2015, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[6]  H. Rugo,et al.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. , 2014 .

[7]  S. Iida,et al.  Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients , 2014, Journal of Cancer.

[8]  R. Gralla,et al.  A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  I. Bondarenko,et al.  Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Rugo,et al.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  G. Phillips,et al.  Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant , 2014, Supportive Care in Cancer.

[12]  J. Herrstedt,et al.  Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin—a phase II study , 2013, Supportive Care in Cancer.

[13]  Cynthia S. Johnson,et al.  Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier on , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Marbury,et al.  Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single‐Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects , 2011, Journal of clinical pharmacology.

[15]  J. Hardwick,et al.  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Mei-Jie Zhang,et al.  Analyzing Competing Risk Data Using the R timereg Package. , 2011, Journal of statistical software.

[17]  A. Molassiotis,et al.  Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009 , 2011, Supportive Care in Cancer.

[18]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  R. Orecchia,et al.  A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  M. Aapro,et al.  Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy , 2010, Supportive Care in Cancer.

[21]  C. Kitagawa,et al.  Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. , 2009, The Lancet. Oncology.

[22]  G. Steineck,et al.  One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient , 2008, Supportive Care in Cancer.

[23]  L. Einhorn,et al.  Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer , 2007, Supportive Care in Cancer.

[24]  P. Dombernowsky,et al.  Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy , 2007, Supportive Care in Cancer.

[25]  Keunchil Park,et al.  Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  H. Muss,et al.  Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–55. , 2006 .

[27]  H. Muss,et al.  Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy , 2005, Cancer.

[28]  R. Gralla,et al.  Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Bodurka,et al.  Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer , 2005, Supportive Care in Cancer.

[30]  R. de Wit,et al.  The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. , 2004, European journal of cancer.

[31]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. de Wit,et al.  Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[34]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[35]  A. Favero,et al.  Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[36]  F. Roila,et al.  Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[38]  G. Laurell,et al.  High‐Dose cisplatin treatment: Hearing loss and plasma concentrations , 1990, The Laryngoscope.

[39]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .